Premium
Low expression of interferon regulatory factor‐1 and identification of novel exons skipping in patients with chronic myeloid leukaemia
Author(s) -
Tzoanopoulos Dimitrios,
Speletas Matthaios,
Arvanitidis Konstantinos,
Veiopoulou Christina,
Kyriaki Sofia,
Thyphronitis George,
Sideras Paschalis,
Kartalis Georgios,
Ritis Konstantinos
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2002.03829.x
Subject(s) - irf1 , interferon regulatory factors , biology , exon , haematopoiesis , cancer research , interferon , myeloid , irf8 , immunology , peripheral blood mononuclear cell , chronic myelogenous leukemia , transcription factor , stem cell , gene , leukemia , genetics , in vitro
Summary. Chronic myeloid leukaemia (CML) is a malignant clonal disorder of the haematopoietic stem cell. Treatment of CML patients with interferon alpha (IFN‐α) has induced haematological and cytogenetic remission. Interferons transcriptionally activate target genes through the JAK–STAT and interferon regulated factors (IRFs) family pathways. Interferon regulated factor‐1 (IRF‐1) is a transcriptional activator of genes critical for cell growth, differentiation and apoptosis. The skipping of exons 2 or 2 and 3 of IRF‐1 in patients with myelodysplastic syndromes and acute myelogenous leukaemia suggests that this factor may have a critical role in leukaemogenesis. The role of IRF‐1 in CML is currently unknown. Therefore, mutational analysis of IRF‐1 was performed and its expression pattern was also studied in CML patients. We studied IRF‐1 in peripheral blood mononuclear cells of 21 patients in chronic phase CML. No point mutations were identified at the cDNA level. Surprisingly, fourfold reduction of full‐length IRF‐1 mRNA expression was established in 17/21 patients compared with normal individuals. Low expression of full‐length IRF‐1 was observed in conjunction with high levels of aberrantly spliced mRNAs, reported for the first time. In three patients who were also analysed during blastic transformation, further reduction of full‐length IRF‐1 mRNA was observed. These findings demonstrate that, in CML patients, IRF‐1 can produce high levels of aberrant spliced mRNAs with subsequent reduction in the levels of full‐length IRF‐1 mRNA. This observation is consistent with the notion that exon skipping may constitute another mechanism of tumour suppressor gene inactivation in this disease.